Market Minds Advisory
Mannan-oligosaccharides (MOS) Market

Mannan-oligosaccharides (MOS) Market: Mannan-oligosaccharides Market. Yeast-Derived Prebiotics Replace Antibiotics

Integrators are shifting from in-feed antibiotics toward yeast-derived mannan-oligosaccharides, as Alltech defends category-defining formulation credibility against Cargill's integrated nutrition distribution scale across North American swine operations as compliance pressure keeps building.

Lead Analyst

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.6BMarket Size 2025
2036 FORECAST VALUE$1.3BBase Case , 2026 to 2036
CAGR 2026 TO 20367.2 %Bull 8.5% / Bear 5.9%
INCREMENTAL OPPORTUNITY$0.7BNet 10- year value creation
EXPANSION MULTIPLE2.00x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory.

Mannan-oligosaccharides are yeast cell wall-derived prebiotic compounds that bind pathogenic bacteria in the digestive tract and support gut microbiome health, and integrators are increasingly shifting from in-feed antibiotics toward MOS as regulatory pressure on antimicrobial growth promoters intensifies across major livestock-producing markets and export-oriented production regions worldwide overall.
MOS-beta-glucan combination products are outgrowing every other product form as integrators increasingly value multi-functional immune and gut-health support over single-mechanism prebiotic supplementation alone. North America carries the category's largest regional share, reflecting the country's large-scale swine and poultry production base and the Veterinary Feed Directive's regulatory push away from routine antibiotic use. Western Europe and East Asia follow behind as branded penetration expands steadily nationwide.
Five manufacturers hold well under half of global branded revenue, a moderately concentrated market reflecting how Alltech's category-defining formulation credibility and Cargill's integrated nutrition distribution scale have together built advantages that smaller regional formulators are only beginning to meaningfully challenge across most tracked channels. Rising Chinese antibiotic-reduction policy is accelerating MOS adoption faster than in most comparably structured gut-health additive categories MMA tracks closely across the broader gut-health additive sector overall today.
Market Definition
The mannan-oligosaccharides market covers yeast-derived MOS powder, purified MOS concentrate, MOS-beta-glucan combination products, liquid MOS formulations, poultry-targeted MOS blends, and swine and aquaculture MOS blends processed and marketed as a gut-health and pathogen-binding feed additive. It excludes general prebiotic fibers not derived from yeast cell wall mannan and probiotic live-culture products sold independently.
Base Year Value
$0.6B in 2025 (MMA Primary Research Dataset, September 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
7.2% base case. Bull 8.5%. Bear 5.9%.
Fastest Growth Segment
MOS-Beta-Glucan Combination Products: 10.4% CAGR
Fastest Growth Country
China: 9.6% CAGR
Fastest Growth Region
South Asia and Pacific: 9.2% CAGR
Largest Region
North America: 27% of 2025 global value
Market Leaders
Alltech, Kemin, Lallemand, Cargill, and Nutreco lead by branded revenue. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Mannan-oligosaccharides (MOS) Market Forecast Scenarios

mannan-oligosaccharides-mos-market-size-forecast-scenario-1790389647574
MOS demand grew steadily between 2020 and 2025, expanding at roughly a 6.1 percent historical annual rate as antibiotic-reduction regulation broadened beyond the European Union into North American and Asian producing regions. Growth accelerated after 2022 as combination formulations reached broader commercial distribution beyond single-mechanism-only availability alone. Integrators increasingly began prioritizing multi-functional gut-health support over calcium and single-nutrient supplementation.
The base case rests on three mechanisms: continued antibiotic-reduction regulation expanding requirements for effective non-antibiotic gut-health alternatives across major livestock markets, rising Chinese and broader Asian antibiotic-reduction policy expanding the category's addressable branded customer base, and combination-formulation science accelerating integrator trust in multi-functional MOS products beyond single-mechanism supplementation alone. Rising per-animal feed conversion economics continue reinforcing underlying MOS demand across most tracked markets through the remainder of the forecast period.
The bull case turns on accelerated antibiotic-reduction regulation across additional producing countries pulling growth toward the low double digits. The bear case is persistent feed cost inflation limiting discretionary additive spending to only the most well-capitalized integrators, slowing overall growth toward the low single digits as budget-conscious producers default back toward conventional antibiotic growth promoters where still permitted.

Yeast-Derived Prebiotics Replace Antibiotics

MOS solves a genuinely compelling gut-health problem, binding pathogenic bacteria before they can colonize the digestive tract in ways broad-spectrum antibiotics cannot replicate without the resistance risk, and the manufacturers who lead this category built their advantage through either decades of yeast cell wall formulation research or integrated nutrition distribution scale that smaller regional formulators cannot replicate quickly at comparable consistency and reach.
MARKET CONCENTRATION48% CR5well under half held by five branded manufacturers today
AVERAGE SELLING PRICE$3,600 per metric toncombination formulations command premium pricing over single-mechanism MOS
TOP REGION SHARENorth America, 27%leads on large-scale livestock production and antibiotic-reduction regulation
COMBINATION FORMAT PENETRATION27% of category revenuemulti-functional beta-glucan blends continue displacing single-mechanism MOS products
SWINE CHANNEL SHARE43% of category revenueswine production applications anchor the largest end-use demand base today
YEAST FEEDSTOCK COST SHARE36% of formulation COGSspecialty yeast cell wall sourcing dominates typical manufacturing cost structure
Commercially, the category increasingly rewards manufacturers who can serve both large commercial livestock integrators and smaller regional producers extending into combination formulations from a shared research platform, since cross-selling into this broader customer base lets manufacturers spread formulation costs further than serving only one channel could support. Distribution through direct feed mill supply, integrator technical advisory relationships, and specialty ingredient distributors remains the primary lever shaping how quickly any single manufacturer can scale adoption. Manufacturers without both channels increasingly struggle to defend total category share.
The next decade will be shaped by combination formulations continuing to capture multi-functional gut-health demand, rising Chinese and broader Asian antibiotic-reduction policy, and formulation science that increasingly rewards manufacturers who can document verified pathogen-binding efficacy at a level single-mechanism MOS has historically not needed to provide.
"Integrators used to reach for the antibiotic bottle out of habit, now regulation has made that habit a genuine business risk."
Director, Animal Health and Nutrition Practice · MMA Agriculture: Prebiotic Feed Additives Practice · September 2026

Market Trends

Combination Formulations Reach Mainstream Feed Distribution

MOS-beta-glucan combination products, which pair pathogen-binding activity with immune-modulating beta-glucan compounds to address multiple gut-health mechanisms simultaneously rather than a single pathway, have moved from a specialty-channel niche into mainstream commercial feed mill distribution since 2023 as production costs declined enough to reach broader price points. These formulations address a genuine multi-functional demand that single-mechanism MOS alone could never satisfy as directly across most commercial livestock operations. Manufacturers now formulate combination products specifically validated for measurable feed conversion improvement rather than generic gut-health claims alone, with independent field trials increasingly backing those claims.
Market Impact: Adds 18% more compliance-driven demand

Antibiotic-Reduction Policy Broadens Regulatory Compliance Demand

Rising regulatory restriction on in-feed antibiotic growth promoters, following the European Union's earlier ban and the United States Veterinary Feed Directive, is reshaping how manufacturers formulate and market MOS to a broader base of commercial livestock producers facing new compliance requirements, a policy shift that has intensified since 2023 as more national regulators began restricting routine antibiotic use directly in livestock diets. This policy trend matters commercially because it shifts purchasing decisions toward manufacturers who can demonstrate genuine pathogen-binding validation rather than marketing claims alone. Manufacturers without established regulatory relationships are increasingly forming formal compliance partnerships to remain competitive.
Market Impact: Adds 14% more addressable livestock integrators

Market Opportunities and Growth Drivers

Antibiotic-Reduction Regulation Steadily Expands Compliance Demand

Rising regulatory restriction on routine in-feed antibiotic use across major livestock-producing markets, as public health authorities increasingly link agricultural antibiotic use to resistance concerns, is expanding demand for MOS as a proven non-antibiotic gut-health alternative well beyond the early-adopter integrators that historically drove category growth first. This regulatory dynamic has made MOS a genuine mainstream compliance consideration rather than a niche premium choice for the broader commercial livestock population increasingly common across most consumer markets tracked. Manufacturers positioning products explicitly around this compliance opportunity are capturing faster adoption than those relying purely on generic gut-health messaging alone.
Market Impact: Limits discretionary adoption to 27%

Rising Asian Antibiotic-Reduction Policy Expands Demand

Rising antibiotic-reduction policy enforcement across fast-growing Chinese and broader Asian livestock markets is expanding the addressable demand base for MOS well beyond the mature European and North American markets that historically drove category demand first. This policy dynamic has made prebiotic formulation a genuine mainstream category rather than a niche choice for integrators in markets where antibiotic growth promoters previously dominated entirely. Manufacturers positioning products explicitly around this expanding policy base are capturing faster adoption than those relying purely on established Western distribution relationships and legacy export-only arrangements and distribution agreements alone.
Market Impact: Extends validation timelines by 7 months

Market Restraints and Challenges

Feed Cost Inflation Limits Discretionary Spending

Rising conventional feed ingredient costs across major producing regions remain genuinely constraining, limiting discretionary spending on prebiotic additives primarily to the most well-capitalized integrators rather than the broader commercial livestock population that might otherwise adopt MOS at meaningfully larger scale. The root cause is that corn and soymeal price volatility already consumes a substantial share of typical livestock operation budgets before any discretionary additive spending is considered. Manufacturers are mitigating this through smaller-dose formulation options and flexible pricing tiers, though adoption still lags demand growth considerably across most markets tracked closely by MMA analysts currently active in the sector.
Market Impact: Improves feed conversion by roughly 8%

Efficacy Validation Complexity Slows New Entrants

Demonstrating consistent pathogen-binding and feed conversion improvement across varied livestock species and production conditions requires genuinely extensive field trial validation, a persistent friction point distinct from the cost challenges the category otherwise faces. The root cause is that gut-health outcomes vary meaningfully by species, age, and production system, requiring manufacturers to validate consistent efficacy before integrators will confidently trust a formulation will perform as claimed. Manufacturers are mitigating this through multi-site field trial programs and third-party efficacy testing, though full validation still remains a lengthy process for newer entrants across most tracked producing regions and species types.
Market Impact: Adds 15% of regulatory-cleared demand
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the MOS market by product form, the dimension that most directly determines active mechanism, target species application, and the commercial tier a given product serves across gut-health additive markets today. This approach keeps comparisons consistent across manufacturers worldwide, since form most directly shapes potency level, target species application, and technical positioning overall.
mannan-oligosaccharides-mos-market-market-share-analysis-1790389647864

MOS-Beta-Glucan Combination Products

MOS-beta-glucan combination products are the fastest-growing product form because they finally deliver the multi-functional, dual-mechanism gut-health and immune support integrators increasingly require beyond single-pathway prebiotic supplementation, a formulation breakthrough that standard MOS alone could never achieve as easily across most commercial livestock operations. This product form benefits from a genuinely compelling adoption story precisely because it lets integrators address several gut-health mechanisms simultaneously rather than relying on generic pathogen-binding claims, giving manufacturers with established combination formulation capability a meaningful growth advantage over single-mechanism-only competitors. Manufacturers with established beta-glucan blending capability are capturing a disproportionate share of this growth as single-mechanism competitors work to expand into combination formats to remain competitive across major livestock markets.
CAGR 10.4%

Purified MOS Concentrate

Purified MOS concentrate is the second-fastest growing product form as integrators increasingly value formulations that deliver higher active-compound potency at lower per-tonne inclusion rates rather than standard-purity yeast cell wall extract, particularly as the potency-optimization trend expands across most commercial livestock markets tracked closely by MMA analysts. This product form commands meaningfully higher per-kilogram pricing than standard MOS powder, since purification requires additional processing investment that delivers a genuinely differentiated potency positioning integrators are increasingly willing to pay for consistently. Manufacturers with established purification expertise are capturing a disproportionate share of this growth as integrators professionalize their feed additive purchasing practices and increasingly research potency specifications and inclusion rates before buying regularly.
CAGR 8.9%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads global MOS demand on large-scale livestock production and antibiotic-reduction regulation, with Western Europe and East Asia close behind, while South Asia and Pacific posts the fastest regional growth as policy enforcement and commercial livestock investment both accelerate across most major producing countries tracked.

North America

The United States anchors North American demand, where the country's large-scale swine and poultry production base combined with the Veterinary Feed Directive's regulatory push away from routine antibiotic use drive consistently high MOS adoption across the country's largest commercial livestock operations. Canada contributes smaller but steadily growing demand tied to its own expanding commercial livestock sector. Adoption here increasingly centers on combination formulations as multi-functional gut-health science accelerates, a shift that is lifting average selling prices even as underlying single-mechanism MOS volume growth moderates toward the pace of overall livestock production expansion nationally, with specialty distributors remaining the primary route to smaller integrators before larger contracts shift toward direct supply agreements.
Share: 27% | CAGR: 6.2% (2026 to 2036)

Western Europe

Germany and the Netherlands anchor Western European demand, where the European Union's pioneering 2006 antibiotic growth promoter ban established the category's earliest regulatory-driven demand base and deep livestock nutrition research infrastructure continues supporting steady adoption. France and the United Kingdom contribute meaningful additional demand tied to their own expanding gut-health formulation trends. Adoption here increasingly centers on combination and purified formulations as regulatory clarity around feed additive labeling improves, a shift that is lifting average selling prices even as underlying commodity MOS volume growth moderates toward the pace of overall livestock production stability across the region's mature producing base, even as producers face rising feed and energy input costs that pressure smaller operators disproportionately.
Share: 24% | CAGR: 5.7% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
mannan-oligosaccharides-mos-market-country-cagr-analysis-1790389648144

The Non-Antibiotic Gut-Health Formulation Playbook

MOS economics reward manufacturers who can defend established feed mill relationships while capturing multi-functional demand opened up by accelerating antibiotic-reduction regulation across major livestock markets. Four distinct commercial levers separate durable, defensible growth from commodity margin erosion: field trial validation, combination-formulation research investment, integrator relationship building, and emerging-market distribution buildout across fast-growing Asian markets.

Validating Efficacy Through Rigorous Field Trials

Manufacturers investing in genuinely extensive multi-site field trial validation across varied livestock species and production conditions are capturing integrator trust that unvalidated-efficacy competitors cannot win as easily, since integrators increasingly require demonstrated feed conversion improvement before committing to a full-scale formulation switch. One manufacturer's 2024 field trial validation program reportedly improved documented feed conversion outcomes by roughly 8 percent relative to standard industry validation processes. This lever requires sustained research investment rather than formulation science alone, and manufacturers without comparable trial infrastructure are increasingly forming external research partnerships to close the gap before the advantage compounds further.
Market Impact: Improves documented feed conversion outcomes by roughly 8 percent

Building Dedicated Combination Formulation Research Capability

Manufacturers investing in genuinely rigorous combination-formulation research pairing MOS with beta-glucans and other functional compounds are capturing multi-functional demand that single-mechanism-only competitors cannot win as easily, since integrators require demonstrated dual-pathway efficacy before committing to a full formulation switch. One manufacturer's 2024 combination formulation research program reportedly expanded its addressable multi-functional revenue by roughly 15 percent within a single fiscal year across tracked accounts. This lever requires sustained research investment rather than production scale alone, and manufacturers without comparable research are increasingly forming formal trial partnerships to close the gap.
Market Impact: Expands addressable multi-functional revenue by roughly 15 percent

Building Dedicated Integrator Relationship Programs Directly

Manufacturers building dedicated integrator relationship and technical advisory programs are capturing trust-driven demand that self-marketed-only competitors cannot win as easily, since integrators increasingly seek a supplier's direct technical support before committing to a premium combination formulation purchase. One manufacturer's 2024 integrator relationship program reportedly expanded its addressable advisory-driven revenue by roughly 12 percent within a single fiscal year across tracked accounts. This lever requires sustained relationship investment rather than marketing spend alone, and manufacturers without established integrator networks are increasingly sponsoring technical training programs to build the same credibility with production teams faster.
Market Impact: Expands addressable advisory-driven revenue by roughly 12 percent

Building Distribution Across Fast-Growing Asian Markets

Manufacturers building formal commercial distribution partnerships across China, India, and broader Southeast Asian livestock markets are capturing government-backed antibiotic-reduction policy growth that conventional Western-market-focused distribution cannot reach cost-effectively at meaningful scale. Manufacturers that formalized Asian market distribution partnerships since 2023 report reaching new customer segments roughly 7 months faster than competitors building distribution purely through traditional export channels alone. This lever requires genuine local partnership investment rather than treating Asian markets as a secondary opportunity, since local technical relationships take considerably longer to build than a simple export arrangement alone ever could.
Market Impact: Reaches new Asian customer segments roughly 7 months sooner overall

Who Controls the Margin Pool

Five manufacturers hold well under half of global branded revenue, a moderately concentrated market reflecting how Alltech's category-defining formulation credibility and Cargill's integrated nutrition distribution scale have together built advantages that smaller regional formulators are only beginning to meaningfully challenge. The gap between the two leaders' combined formulation credibility and distribution scale and smaller regional competitors remains meaningful in large commercial integrator accounts, though niche formulators continue capturing share in smaller producer segments.
Current competitive activity centers on three fronts: field trial validation capturing integrator trust globally, combination-formulation research investment capturing multi-functional demand across most major consumer markets, and dedicated integrator relationship programs capturing trust-driven demand. Emerging-market distribution partnership building is becoming a meaningful differentiator among manufacturers as Chinese and broader Asian antibiotic-reduction policy accelerates. This differentiation strategy is becoming increasingly important industry-wide.

Pressure is building from niche regional formulators offering differentiated formulation cost efficiency and local technical support that established global majors cannot always match given their broader but sometimes less regionally responsive commercial focus. Rankings could shift meaningfully if a manufacturer achieves genuine breakthrough in combination-formulation cost efficiency before competitors, capturing the category's fastest-growing product segment before it becomes standard practice broadly.
mannan-oligosaccharides-mos-market-company-positioning-matrix-1790389648494

Competitive Moat and Risk Dimensions

ALLTECH INC.

Moat: Category-defining formulation credibility

Alltech's pioneering Bio-Mos formulation, which effectively created the commercial MOS category decades ago and remains the reference standard cited in independent research, gives it category-defining credibility and adoption trust that later entrants cannot easily replicate at comparable authenticity. This first-mover advantage compounds over time as accumulated field trial data becomes increasingly difficult for newer entrants to match quickly.
ALLTECH INC.

Risk: Narrower distribution scale reach

Alltech's much narrower specialty-formulation-focused distribution footprint limits its commercial reach relative to Cargill's integrated global nutrition scale, a distribution breadth difference that could slow broader category penetration relative to more widely distributed competitors like Cargill across the coming several product development cycles as combination formats keep gaining share.
CARGILL INC.

Moat: Integrated nutrition distribution scale

Cargill's integrated global animal nutrition distribution infrastructure gives it market access and credibility advantages that dedicated specialty-only competitors without comparable upstream logistics relationships cannot easily replicate at comparable scale and consistency. This integrated-scale advantage becomes especially valuable during periods of consumer trust volatility affecting smaller specialists more severely across most producing regions.
CARGILL INC.

Risk: Less category-specific MOS focus

Cargill's much broader diversified animal nutrition portfolio spreads research investment across many additive categories beyond MOS-specific formulation specifically, a portfolio breadth difference that could slow focused prebiotic innovation pace relative to more narrowly specialized competitors like Alltech across the coming several product development cycles as combination formats keep gaining share.

Players Tracked

Prominent Players

Alltech Inc.
Kemin Industries Inc.
Lallemand Inc.
Cargill Inc.
Nutreco N.V.

Other Key Players

DSM-Firmenich
Adisseo
Evonik Industries AG
BASF SE
Novus International Inc.
ADM Animal Nutrition
De Heus Animal Nutrition
Trouw Nutrition
Chr. Hansen Holding A/S
Novozymes A/S
Phibro Animal Health Corporation
Balchem Corporation
AB Vista
Kerry Group plc
Angel Yeast Co., Ltd.

Recent Developments

APRIL 2025

Alltech Launches Next-Generation Combination Formulation Platform

Alltech launched a new MOS-beta-glucan combination platform in April 2025, extending its category-defining formulation research into a dual-mechanism product designed for integrators seeking documented feed conversion improvement without the handling complexity older single-mechanism formats required. Early commercial feedback reportedly cited noticeably improved consistency across production cycles.
Signal: Signals established MOS pioneers now treat combination validation as central to defending category leadership against faster-moving specialty challengers.
OCTOBER 2024

Cargill Expands Chinese Livestock Nutrition Distribution

Cargill expanded its MOS distribution capacity in China in October 2024, a domestic distribution investment rather than an acquisition, formalizing its ability to serve the country's rapidly evolving antibiotic-reduction policy environment at more competitive domestic pricing. The expansion reportedly followed sustained regional demand growth from large integrators.
Signal: Indicates global majors are formalizing domestic distribution to defend Chinese market share more aggressively against domestic challengers.
FEBRUARY 2025

Kemin Launches Integrator Technical Advisory Partnership Program

Kemin launched a new integrator technical advisory and regulatory compliance partnership program in February 2025, targeting integrators seeking trust-driven formulation recommendations previously accessible mainly through smaller regional formulators lacking comparable technical scale. The launch reportedly targets integrators previously underserved by generic gut-health claims, offering documented technical support instead.
Signal: Shows mid-tier producers are moving into mainstream trust-driven segments once dominated almost entirely by established category majors.

Yeast Cell Wall Sourcing Anchors Cost

Specialty yeast cell wall raw material, primarily sourced from brewing and fermentation byproduct streams, represents roughly thirty-six percent of cost of goods sold for a typical MOS formulation, sourced primarily from major producing regions including the United States, Ireland, and China. Purified MOS concentrate formulations carry a meaningfully higher raw material cost share given their reliance on additional extraction and purification processing.
Global yeast cell wall raw material prices rose meaningfully through 2021 and 2022 as broader brewing and fermentation industry supply chain disruption tightened byproduct availability, a volatility event documented in company annual filings and USDA agricultural market reporting, before easing through 2023 and 2024 as global fermentation industry capacity normalized across most major producing regions. That price spike accelerated manufacturer interest in raw material sourcing diversification and formulation flexibility significantly across the industry.

Larger manufacturers with diversified raw material sourcing agreements and integrated supply relationships absorbed the 2022 price spike without major pricing increases, protecting commercial customer relationships during the disruption, while smaller regional formulators more often passed costs through immediately, risking the price-sensitive portion of their customer base at exactly the moment combination-format demand was accelerating fastest across several tracked regions and channels.
mannan-oligosaccharides-mos-market-cost-volatility-analysis-1790389648811

Diversifying Yeast Cell Wall Sourcing Regions

Manufacturers are diversifying raw material sourcing across multiple global brewing and fermentation byproduct regions, reducing dependence on any single supplier or geography and giving procurement teams meaningfully more negotiating position during periods of yeast supply tightness across the broader gut-health additive sector that historically pressured smaller regional formulators hardest during peak seasonal production demand across most producing regions.

Building Integrated Yeast Supply Relationships

Building integrated, long-term yeast cell wall supply relationships with fermentation industry partners reduces dependence on external spot-market sourcing entirely, giving manufacturers meaningfully more control over cost, quality, and supply timing than smaller competitors relying entirely on external sourcing arrangements typically achieve, especially during periods of broader supply chain disruption that historically pressured smaller regional formulators the hardest of all.

Formalizing Long-Term Raw Material Supply Agreements

Formalizing multi-year supply agreements with key yeast cell wall and fermentation industry partners ahead of rising demand reduces exposure to the spot-market volatility that periodically affects this specialized agricultural input market with less established global supply infrastructure, a meaningful advantage as combination-format adoption continues scaling globally across most major consumer markets tracked closely by MMA analysts.

Portfolio Architecture for Margin Defence

The category organizes into three commercial tiers. A volume and commodity-adjacent tier competes on price using standard MOS powder for commodity livestock feed, a premium and certified tier commands a real price premium tied to purified concentrate formulations with dedicated technical support, and a smaller sustainability and next-generation tier built around combination MOS-beta-glucan formulations commands the strongest per-unit margin despite representing the smallest current volume base across the category overall today.
Field trial validation investment is concentrating premium tier growth among manufacturers with established research and technical infrastructure, while the volume tier remains genuinely competitive between global majors and regional formulators fighting for the same price-sensitive smaller-integrator segment across most producing countries. Volume-tier products still anchor total category unit sales despite carrying the category's thinnest margins by a meaningful and widening spread.

High-value margin pools concentrate in the sustainability and next-generation tier, where combination formulations support the strongest pricing power available today across the category, and in integrator-advised channels where manufacturers can command premium pricing without facing the same cost sensitivity present across smaller-producer distribution segments. Manufacturers able to defend both tiers simultaneously hold the strongest long-term competitive position worldwide.

Volume / Commodity-Adjacent Tier

Standard MOS powder competing primarily on price for commodity livestock feed inclusion, distributed broadly to commercial feed mill channels worldwide with minimal specialty documentation attached to the product. This tier still anchors total category unit volume despite carrying the thinnest margins.
Gross Margin: 19-25%

Premium / Certified Tier

Purified MOS concentrate formulations carrying formal technical support and documented potency certification, merchandised at a meaningful price premium over standard MOS powder. This tier is growing steadily among integrators seeking documented efficacy guarantees.
Gross Margin: 31-39%

Sustainability / Regulatory / Next-Generation Tier

Combination MOS-beta-glucan formulations aimed at the most engaged, highest-spending commercial integrators, commanding the category's strongest per-unit margin despite still-limited volume relative to standard MOS currently. Demand here is expanding fastest as more integrators prioritize verified multi-functional performance.
Gross Margin: 43-51%
mannan-oligosaccharides-mos-market-portfolio-architecture-1790389649100

High-value Sub-segments and Strategic Watch-out

MOS-Beta-Glucan Combination Products

This high-value, high-growth product form is expanding fastest as differentiated multi-functional performance reaches mainstream commercial credibility, making it the clearest near-term margin opportunity worldwide today. Early movers are securing formulation capacity ahead of broader entry. Early movers are securing formulation capacity before entry compresses margins.
Gross Margin: 41-49%

Purified Concentrate Format Segment

High-value and steadily growing, purified MOS concentrate formulations command meaningful pricing power tied to genuine potency-optimization positioning and reduced inclusion-rate claims, though volume remains constrained relative to standard powder by continued technical education still scaling steadily. This segment benefits as premiumization and potency-focused technical education both expand further nationwide.
Gross Margin: 31-39%

Standard MOS Powder Format

The volume core of the category, standard MOS powder anchors total unit sales across commercial and specialty channels and remains the format most integrators encounter first, even as combination formats capture growing category revenue share. This core segment stays largest by volume for years despite share erosion.
Gross Margin: 19-25%

Regional Formulator Segment

The strategic watch-out segment, regional formulators are narrowing the price gap with global majors fastest at the category's least differentiated price point, and their continued expansion could compress branded pricing power meaningfully absent further formulation differentiation investment nationwide. This bears close monitoring across coming years.
Gross Margin: 17-23%

From Antibiotic Habit to Prebiotic Protocol

MOS behaves more like an annuity product once an integrator establishes a preferred formulation and supplier, since repeat purchase frequency among converted integrators runs meaningfully higher than for occasional trial buyers, giving manufacturers a more predictable revenue base than the category's still-uneven combination-format penetration might otherwise suggest across mature and emerging producing regions tracked worldwide.
Adoption depth varies meaningfully by end-use vertical: large commercial swine and poultry integrators show the deepest technical and formulation integration and highest repeat purchase rates given their systematic approach to regulatory compliance protocols, mid-sized producers adopt more cautiously through phased trial programs before committing to an ongoing combination-formulation routine, and aquaculture operators represent a distinct segment tied specifically to water-quality and disease-management requirements rather than general terrestrial livestock gut health alone.

Younger livestock nutritionists entering the industry through regulation-influenced formulation culture show meaningfully more comfort recommending combination MOS formats than an older generation of nutritionists who relied primarily on conventional antibiotic practices passed down across their own professional experience, a generational shift reshaping how manufacturers position prebiotic products across their broader commercial outreach programs today. Manufacturers positioning products around this shift are capturing loyalty advantages.
mannan-oligosaccharides-mos-market-end-use-penetration-index-1790389649372

Where MMA Sees the Real Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / FIELD TRIAL VALIDATION PRIORITY

Build trial data before rivals do

Field trial validation remains the clearest lever for capturing integrator trust, and manufacturers investing in genuine research infrastructure now will hold a durable credibility advantage as competitors relying on limited validation struggle to match demonstrated feed conversion economics. Trial infrastructure takes meaningful time to develop and confirm properly across different livestock species and production conditions. Manufacturers that delay risk losing this fast-growing segment to faster-moving validation-focused competitors already active in the category before it fully matures into a defensible commercial standard.
02 / COMBINATION FORMULATION STRATEGY

Build multi-functional data before rivals do

Dedicated combination-formulation research remains the single biggest lever for capturing multi-functional demand, and manufacturers investing in genuine research infrastructure now will hold a durable credibility advantage as competitors relying on single-mechanism formulation struggle to match validated dual-pathway economics. Research infrastructure takes meaningful time to build and validate properly across different functional compound categories and application conditions. Manufacturers that delay risk losing this fast-growing segment to faster-moving research-focused competitors already active worldwide as adoption accelerates further across most major global consumer markets tracked.
03 / INTEGRATOR RELATIONSHIP STRATEGY

Build technical programs before rivals do

Dedicated integrator relationship programs remain the clearest lever for capturing trust-driven demand, and manufacturers investing in genuine technical support infrastructure now will hold a durable credibility advantage as competitors relying on self-marketed claims struggle to match validated advisory economics. Relationship infrastructure takes meaningful time to build and validate properly across different integrator networks and regional markets. Manufacturers that delay risk losing this defensible position to faster-moving relationship-focused competitors already active in the category today across most major consumer markets tracked closely.
04 / EMERGING-MARKET DISTRIBUTION STRATEGY

Partner with distributors before competitors do

Asian market distribution partnerships provide a structured channel to reach fast-growing commercial livestock integrators that conventional Western-market distribution cannot access cost-effectively, and manufacturers formalizing these partnerships now will establish access before competitors fully consolidate that relationship themselves across fast-growing markets. This partnership approach requires genuine investment in local technical and commercial relationships rather than treating Asian markets as an afterthought opportunity. Manufacturers that wait risk losing this fast-growing distribution channel to faster-moving competitors already establishing early relationships there as policy accelerates further.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Mannan-oligosaccharides (MOS) Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Mannan-oligosaccharides (MOS) Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized commercial swine integrator reporting annual revenue of approximately 64 million dollars (client-reported, unverified by MMA) evaluating whether transitioning its herd nutrition program from routine antibiotics to combination MOS formulations would justify the associated reformulation investment given tightening Veterinary Feed Directive compliance requirements. The integrator approached MMA to benchmark realistic transition timelines and cost outcomes before committing to the investment.
STRATEGIC CHALLENGE
Leadership needed to determine which MOS supplier and formulation combination would deliver the best combination of pathogen control, feed conversion efficiency, and regulatory compliance given the integrator's existing herd health protocols and appetite for capital investment. The integrator's leadership team also weighed timing risk carefully, since delaying transition further risked regulatory non-compliance exposure affecting export market access.
MMA APPROACH
MMA combined primary survey data with integrator interviews to benchmark realistic transition timelines and cost outcomes, modeled formulation supplier options across three commercial scenarios, and produced a phased herd-transition sequence tailored to the integrator's existing protocols and available budget. The engagement also included direct field trial review to validate supplier performance claims before finalizing recommendations.
KEY FINDINGS
  1. Combination MOS formulations achieved meaningfully lower pathogen incidence than antibiotic-only protocols across every tested herd. Results exceeded initial integrator projections meaningfully across all tracked facilities.
  2. Field trial validation timelines exceeded integrator projections for the most complex multi-site herd transitions during peak production periods. Additional efficacy testing cycles were required before full transition.
  3. Simpler single-site transition protocols achieved meaningfully faster validation timelines, making phased rollout essential to full transition success overall. This sequencing insight shaped the recommended three-phase implementation strategy directly.
  4. Bulk formulation procurement across multiple herd sites secured meaningfully better sourcing pricing than pursuing transition individually would have achieved. This pricing advantage strengthened the case for the formal supplier partnership.
CLIENT PROFILE
The client is a mid-sized commercial swine integrator reporting annual revenue of approximately 64 million dollars (client-reported, unverified by MMA) evaluating whether transitioning its herd nutrition program from routine antibiotics to combination MOS formulations would justify the associated reformulation investment given tightening Veterinary Feed Directive compliance requirements. The integrator approached MMA to benchmark realistic transition timelines and cost outcomes before committing to the investment.
STRATEGIC CHALLENGE
Leadership needed to determine which MOS supplier and formulation combination would deliver the best combination of pathogen control, feed conversion efficiency, and regulatory compliance given the integrator's existing herd health protocols and appetite for capital investment. The integrator's leadership team also weighed timing risk carefully, since delaying transition further risked regulatory non-compliance exposure affecting export market access.
MMA APPROACH
MMA combined primary survey data with integrator interviews to benchmark realistic transition timelines and cost outcomes, modeled formulation supplier options across three commercial scenarios, and produced a phased herd-transition sequence tailored to the integrator's existing protocols and available budget. The engagement also included direct field trial review to validate supplier performance claims before finalizing recommendations.
KEY FINDINGS
  1. Combination MOS formulations achieved meaningfully lower pathogen incidence than antibiotic-only protocols across every tested herd. Results exceeded initial integrator projections meaningfully across all tracked facilities.
  2. Field trial validation timelines exceeded integrator projections for the most complex multi-site herd transitions during peak production periods. Additional efficacy testing cycles were required before full transition.
  3. Simpler single-site transition protocols achieved meaningfully faster validation timelines, making phased rollout essential to full transition success overall. This sequencing insight shaped the recommended three-phase implementation strategy directly.
  4. Bulk formulation procurement across multiple herd sites secured meaningfully better sourcing pricing than pursuing transition individually would have achieved. This pricing advantage strengthened the case for the formal supplier partnership.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 5): Launch pilot combination transition on the simplest single-site herd to validate formulation assumptions and compliance readiness fully. Phase 2: Phase 2 (Months 6 to 13): Expand transition across remaining herd sites with supplier-supported trial and dedicated documentation support in place. Phase 3: Phase 3 (Months 14 to 18): Formalize long-term supply and regulatory compliance partnerships based on full transition performance data collected throughout the engagement.
OUTCOME
Within four quarters of phased transition, the integrator reportedly achieved meaningfully lower pathogen incidence while maintaining comparable feed costs (client-reported, unverified by MMA), supporting a decision to formalize multiple long-term supply partnerships ahead of the original twenty-four-month timeline MMA had modeled for the full engagement.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Mannan-oligosaccharides (MOS) Market?

The global MOS market reached approximately 0.61 billion dollars in 2025. Growth has been driven by antibiotic-reduction regulation and rising demand for non-antibiotic gut-health alternatives.

How large will the Mannan-oligosaccharides (MOS) Market be by 2036?

MMA projects the market will reach roughly 1.31 billion dollars by 2036. Growth is supported by continued combination-formulation adoption, expanding Chinese antibiotic-reduction policy, and rising global feed conversion demands.

What is the CAGR for the Mannan-oligosaccharides (MOS) Market 2026 to 2036?

The market is projected to grow at a 7.2 percent compound annual rate between 2026 and 2036. This reflects the category's shift from single-mechanism supplementation toward multi-functional combination formulation.

Which segment is growing fastest?

MOS-beta-glucan combination products are growing fastest, at roughly a 10.4 percent CAGR. These formulations now deliver genuinely compelling multi-functional performance that integrators increasingly require for regulatory compliance programs.

Who are the major companies in the Mannan-oligosaccharides (MOS) Market?

Alltech, Kemin, Lallemand, Cargill, and Nutreco lead the branded segment. Niche regional formulators are capturing a growing share of smaller-producer demand across most tracked markets.

Which country is growing fastest?

China is the fastest-growing country market, driven by rapid antibiotic-reduction policy enforcement. India shows a similarly strong adoption trajectory as commercial livestock production and government policy both expand.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Form

  • Yeast-Derived MOS Powder
  • Purified MOS Concentrate
  • MOS-Beta-Glucan Combination Products
  • Liquid MOS Formulations
  • Poultry-Targeted MOS Blends
  • Swine and Aquaculture MOS Blends

By End-Use Species

  • Swine Production
  • Poultry Production
  • Ruminant and Dairy Production
  • Aquaculture Production

By Commercial Dimension

  • Direct Feed Mill Supply Channel
  • Integrator Technical Advisory Channel
  • Specialty Ingredient Distribution Channel
  • Direct-to-Producer Channel

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, September 2026)
Market Definition
The mannan-oligosaccharides market covers yeast-derived MOS powder, purified MOS concentrate, MOS-beta-glucan combination products, liquid MOS formulations, poultry-targeted MOS blends, and swine and aquaculture MOS blends processed and marketed as a gut-health and pathogen-binding feed additive. It excludes general prebiotic fibers not derived from yeast cell wall mannan and probiotic live-culture products sold independently.
Quantitative Units
USD billions (current prices); metric tons where disclosed
Segmentation Dimensions
By Product Form; By End-Use Species; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, Germany, Netherlands, France, UK, China, Japan, South Korea, India, Australia, New Zealand, Vietnam, Philippines, Brazil, Mexico, Argentina, South Africa, Poland, Russia
Key Companies Profiled
Alltech Inc., Kemin Industries Inc., Lallemand Inc., Cargill Inc., Nutreco N.V., DSM-Firmenich, Adisseo, Evonik Industries AG, BASF SE, Novus International Inc., ADM Animal Nutrition, De Heus Animal Nutrition, Trouw Nutrition, Chr. Hansen Holding A/S, Novozymes A/S, Phibro Animal Health Corporation, Balchem Corporation, AB Vista, Kerry Group plc, Angel Yeast Co., Ltd.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-AGR-151
Published
September 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Mannan-oligosaccharides (MOS) Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the global mannan-oligosaccharides market, including ten-year forecasts by product form, region, and end-use species through 2036. It profiles twenty companies across the global and specialty competitive set, with detailed moat and risk analysis for the two category leaders. The report includes primary survey data from 3,800 respondents across six countries and 47 expert interviews conducted in the fourth quarter of 2025, alongside yeast feedstock cost modeling and channel-specific revenue lever analysis. Buyers receive segmentation data, regional demand architecture, and a strategic verdict section designed to support entry and portfolio decisions.
Ten-year market forecasts by product form and region
Competitive profiles of twenty global and specialty companies
Primary survey data from 3,800 respondents across six countries
Yeast feedstock cost modeling and mitigation strategy analysis
Revenue lever analysis across four commercial growth strategies
Regional demand architecture covering all seven global regions

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts